{"id":1250,"date":"2026-11-02T08:59:27","date_gmt":"2026-11-02T06:59:27","guid":{"rendered":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/"},"modified":"2026-11-02T09:03:37","modified_gmt":"2026-11-02T07:03:37","slug":"biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/","title":{"rendered":"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia. For market access teams, the work begins at the opinion.<\/strong><\/p>\n<h2>What was recommended<\/h2>\n<p>EMA&#8217;s highlights list both products among six new medicines recommended. The Commission decision normally follows within 67 days, after which the products can be marketed in the EU subject to national steps.<\/p>\n<h2>Two very different settings<\/h2>\n<ul><li><strong>Ophthalmology.<\/strong> Intravitreal products involve hospital pharmacy purchasing and specialist prescribing, so tendering and hospital formularies are important routes.<\/li><li><strong>Supportive oncology care.<\/strong> Filgrastim is used across many treatment settings, where price competition and prescribing habits are decisive.<\/li><\/ul>\n<h2>Greek market access considerations<\/h2>\n<p>Biosimilar uptake depends on pricing rules, reimbursement listing, hospital procurement and prescriber confidence. Evidence on equivalence is established through the EU regulatory assessment, and EMA and the HMA have published statements supporting interchangeability of authorised biosimilars, but communication to clinicians remains important.<\/p>\n<h2>Timing<\/h2>\n<p>Launch readiness requires submission of national pricing and reimbursement files, packaging and labelling in Greek, pharmacovigilance set-up and distribution agreements. Doing these in parallel with the Commission decision shortens the time to patient access.<\/p>\n<h2>How PQRA helps<\/h2>\n<p>PQRA supports biosimilar developers and distributors with national pricing and reimbursement submissions, labelling and artwork, pharmacovigilance set-up and launch readiness in Greece.<\/p>\n<p><strong><a href=\"\/el\/contact\/\">Contact PQRA to discuss your situation<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia. For market access teams, the work begins at the opinion. What was recommended EMA&#8217;s highlights list both products among six new medicines recommended. The Commission decision normally follows within 67 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1289,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market - PQRA\" \/>\n<meta property=\"og:description\" content=\"Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia. For market access teams, the work begins at the opinion. What was recommended EMA&#8217;s highlights list both products among six new medicines recommended. The Commission decision normally follows within 67 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T06:59:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T07:03:37+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u03bb\u03b5\u03c0\u03c4\u03cc\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market\",\"datePublished\":\"2026-11-02T06:59:27+00:00\",\"dateModified\":\"2026-11-02T07:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-20.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/\",\"name\":\"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-20.png\",\"datePublished\":\"2026-11-02T06:59:27+00:00\",\"dateModified\":\"2026-11-02T07:03:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-20.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-20.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/","og_locale":"el_GR","og_type":"article","og_title":"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market - PQRA","og_description":"Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia. For market access teams, the work begins at the opinion. What was recommended EMA&#8217;s highlights list both products among six new medicines recommended. The Commission decision normally follows within 67 [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/","og_site_name":"PQRA","article_published_time":"2026-11-02T06:59:27+00:00","article_modified_time":"2026-11-02T07:03:37+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"1 \u03bb\u03b5\u03c0\u03c4\u03cc"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market","datePublished":"2026-11-02T06:59:27+00:00","dateModified":"2026-11-02T07:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-20.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/","url":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/","name":"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-20.png","datePublished":"2026-11-02T06:59:27+00:00","dateModified":"2026-11-02T07:03:37+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-20.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-20.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/biosimilar-opinions-in-october-2026-ranibizumab-and-filgrastim-enter-the-pipeline-to-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1250"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1250\/revisions"}],"predecessor-version":[{"id":1290,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1250\/revisions\/1290"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1289"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}